Abstract Purpose:We hypothesized that deregulated corepressor actions, with associated histone deacetylation activity, epigenetically suppressed vitamin D receptor (VDR) responsiveness and drives resistance towards 1a,25-dihydroxyvitamin D 3 . Experimental Design: Profiling, transcriptional, and proliferation assays were undertaken in 1a,25(OH) 2 D 3 -sensitive MCF-12A nonmalignant breast epithelial cells, a panel of breast cancer cell lines, and a cohort of primary breast cancer tumors (n = 21). Results: Elevated NCoR1 mRNA levels correlated with suppressed regulation of VDR target genes and the ability of cells to undergo arrest in G 1 of the cell cycle. A similar increased ratio of corepressor mRNA to VDR occurred in matched primary tumor and normal cells, noticeably in estrogen receptor a^negative (n = 7) tumors. 1a,25(OH) 2 D 3 resistance in cancer cell lines was targeted by cotreatments with either 1a,25(OH) 2 D 3 or a metabolically stable analogue (RO-26-2198) in combination with either trichostatin A (TSA; histone deacetylation inhibitor) or 5-aza-2V-deoxycytidine (DNA methyltransferase inhibitor). Combinations of vitamin D 3 compounds with TSA restored VDR antiproliferative signaling (target gene regulation, cell cycle arrest, and antiproliferative effects in liquid culture) to levels which were indistinguishable from MCF-12A cells. Conclusions: Increased NCoR1 mRNA is a novel molecular lesion in breast cancer cells, which acts to suppress responsiveness of VDR target genes, resulting in 1a,25(OH) 2 D 3 resistance and seems to be particularly associated with estrogen receptor negativity.This lesion provides a novel molecular diagnostic and can be targeted by combinations of vitamin D 3 compounds and low doses of TSA.
The nuclear receptor superfamily regulates diverse signals that are central to the formation and homeostasis of the mammary gland. The postgenomic description of the superfamily conjoined with profiling approaches (1) reveals that breast myoepithelial and epithelial cells express a rich cohort of nuclear receptors, many of which display overt nutrient-sensing capacity for micronutrients and macronutrients alongside the estrogen receptors (ERa and ERh; refs. 2 -6) .
Several of the diet-sensing nuclear receptors, such as the VDR, preferentially form heterodimers with retinoid X receptors whereas the ERs preferentially heterodimerize with one another. For the nuclear receptors to regulate transcriptional programs, these dimers must be contained as subunits in either large gene coactivator or corepressor complexes. In the absence of ligand, receptors exist in an apo state as part of large complexes (f2.0 MDa; ref. 7) , associated with corepressors (e.g., NCoR1, NCoR2/SMRT, and TRIP15/Alien), and bound to response element sequences. These complexes actively recruit a range of enzymes that posttranslationally modify histone tails (e.g., histone deacetylases and methyltransferases) and thereby maintain a locally closed chromatin structure around response element sequences (8) . Ligand binding induces a so-called holo receptor state, facilitating the association of the receptor dimer with coactivator complexes. These receptor coactivator complexes coordinate the recruitment of an antagonistic battery of enzymes and induce the reorganization of local chromatin to facilitate gene transcription (9 -11) . Thus, cofactor expression is critical to determine cellular sensitivity to ligand although the specificity of receptor and either coactivator or corepressor interactions remains to be established fully.
In vivo studies on vdr knockout mice show the requirement for 1a,25-dihydroxyvitamin D 3 [1a,25(OH) 2 D 3 ] for mammary gland function and differentiation (12) . Parallel studies by ourselves and others have found epidemiologic links between the incidence of breast cancers and low serum 25(OH)D 3 levels (13, 14) ; the risk is compounded by specific VDR polymorphisms (15, 16) . In vitro studies show that MDA-MB-231 and other cancer cells show a spectrum of insensitivity toward 1a,25(OH) 2 D 3 (17, 18) . Taken together, these data suggest that functional VDR-mediated signaling is required for correct gland function and that 1a,25(OH) 2 D 3 -deficient environments and/or cellular mechanisms which suppress sensitivity to 1a,25(OH) 2 D 3 are both associated with malignancy. The mechanisms for cellular 1a,25(OH) 2 D 3 insensitivity in breast cancer are as yet unclear and limit therapeutic applications, although a lack of a functional VDR alone cannot explain resistance (17, 19) .
We have previously proposed and investigated epigenetic mechanisms as the basis for corruption of VDR signaling in prostate cancer (20, 21) . In the current study, we have used these findings for the basis of investigation of nuclear receptor corepressor expression and activity to derive breast cancer insensitivity towards 1a,25(OH) 2 D 3 . By contrast, other workers have suggested that NCoR1 is down-regulated in ERa-positive breast cancers as a mechanism of escaping endocrine restraint by tamoxifen (22 -25) . It thus remains to be resolved which are the pivotal interactions of corepressors, either to drive insensitivity to antimitotic receptors such as the VDR or to play a role in evolving tamoxifen resistance. In the current study, we have investigated the potential for corepressormediated mechanisms to attenuate VDR signaling pathways in both ERa-positive and ERa-negative cell line and tumor backgrounds.
Materials and Methods
Vitamin D 3 compounds and epigenetic inhibitors. 1a,25(OH) 2 D 3 and a potent analogue that is resistant to CYP24 metabolism, 1a,25-dihydroxy-16,23Z-diene-26,27-hexafluoro-19-nor vitamin D 3 (RO-26-2198; refs. 26 -31), trichostatin A (TSA), and 5-aza-2V -deoxycytidine (5-aza-dCyd; Sigma, Poole, United Kingdom) were all stored as 1 mmol/L stock solutions in ethanol at À20jC.
Cell culture. The breast cancer cell lines T-47D, ZR-75-1, MCF-7, and MDA-MB-231 were supplemented with 100 units/mL penicillin, 100 Ag/mL streptomycin, and 10% fetal bovine serum (Life Technologies, Inc., Paisley) in RPMI medium and passaged by trypsinizing with trypsin-EDTA (Life Technologies). MCF-12A cells were a generous gift of Prof. H. Phillip Koeffler (Cedars-Sinai Medical Ctr/University of California at Los Angeles School of Medicine, Los Angeles, CA). These cells are a nontumorigenic epithelial cell line established from tissue taken at reduction mammoplasty from a nulliparous patient with fibrocystic breast disease that contained focal areas of intraductal hyperplasia (32) . They are not tumorigenic in immunosuppressed mice but do form colonies in semisolid medium. These cells were cultured in a 1:1 mixture of DMEM and Ham's F12 medium, 20 ng/mL epidermal growth factor, 100 ng/mL cholera toxin, 0.01 mg/mL insulin and 500 ng/mL hydrocortisone, 95%; horse serum, 5%. All cells were grown at 37jC in a humidified atmosphere of 5% CO 2 in air.
mRNA from tumor panels. Matched tumor and normal tissues were obtained from biopsies/resection specimens of Caucasian female patients who had undergone surgery for invasive ductal breast cancer at St. George's Hospital (London, United Kingdom). Age at diagnosis of primary tumor (range, 35-88 years) and estrogen receptor status were validated from histopathologic reports and patient medical records. The study received local ethical approval from St. George's Hospital Medical School Ethics Committee. Total RNA was extracted using the RNeasy and the Lipid Tissue Mini Kit (Qiagen, Crawley, United Kingdom). Briefly, a piece of breast tissue, f2 mm 3 in size, was excised from the relevant frozen surgical sample, which had been stored in liquid nitrogen. The tissue was placed directly into 1 mL of lysis reagent and homogenized using a rotor-stator homogenizer (IKA-Werke, Staufen, Germany). Total RNA was then extracted according to the instructions of the manufacturer, with one modification: before ethanol washes, DNA digestion was carried out using RQ1 Rnase-Free DNase (Promega, Southampton, United Kingdom) by the addition of 10 AL of RQ1 DNase, 10 AL of 10Â RQ1 buffer, and 80 AL of H 2 O to each column, followed by 15-minute incubation at room temperature. RNA was eluted in 30 AL of RNase-free water and stored at À70jC.
Liquid proliferation assay. The action of individual agents alone and in combination was examined using a bioluminescent technique to measure changes in liberated cellular ATP per treatment well (ViaLight HS, LumiTech, Nottingham, United Kingdom), with previously optimized conditions, according to the instructions of the manufacturer. This assay has proved to yield a linear relationship between ATP levels in a test well and a wide range of cell numbers. Therefore, inhibition of proliferation can be readily measured in test wells by measuring the decrease in ATP levels relative to untreated wells (20) .
Briefly, cells were plated in 96-well white-walled tissue culture treated plates (Fisher Scientific Ltd., Loughborough, United Kingdom) at either 2 Â 10 3 per well (MCF-7 and MDA-MB-231) or 4 Â 10 3 per well (MCF-12A, ZR-75-1, and T47-D). Growth media containing varying concentrations of 5-aza-dCyd, TSA, 1a,25(OH) 2 D 3 , and vitamin D 3 analogue were added to a final volume of 100 AL/well and the plates were incubated for 96 hours, with redosing after 48 hours. After the incubation period, 100 AL of nucleotide releasing reagent were added to each well and left for 15 minutes at room temperature. Liberated ATP was quantitated by adding 20 AL of ATP monitoring reagent (containing luciferin and luciferase) and measuring luminescence with a microplate luminometer (Berthold Detection Systems, Fisher Scientific). ATP levels were recorded in relative luciferase units and inhibition of proliferation was expressed as a percentage of control. All experiments were repeated in triplicate wells in three separate experiments.
Clonal proliferation in soft agar. Trypsinized and washed single-cell suspensions of cells from 80% confluent cultures were enumerated and plated into 24-well flat-bottomed plates (Costar, Bucks, United Kingdom) using a two-layer soft-agar system with a total of 1 Â 10 3 cells per well in a total volume of 600 AL/well. Both layers were prepared with sterile agar (1%) that had been equilibrated previously at 42jC. TSA and/or 1a,25(OH) 2 D 3 was added to the wells before the addition of the feeder layer (20% FCS, 40% 2Â RPMI, 40% agar). The cells were mixed into the top layer [20% FCS, 30% 2Â RPMI, 30% agar, 18% medium containing cells, 1% L-glutamine (100 mg/mL), 1% h-mercaptoethanol (1 mmol/L)] and plated onto the preset under layer. After 14 days of incubation at 37jC in a humidified atmosphere of CO 2 in air, the colonies (>50 cells) were counted under an inverted microscope. All experiments were done thrice in triplicate.
Cell cycle analysis. The effect on the cell cycle distribution of vitamin D 3 compounds, alone and in combination with TSA, was measured by staining cell DNA with propidium iodide. Briefly, T25 flasks were seeded with 2.5 Â 10 5 subconfluent, exponentially proliferating cells, exposed to either agent at time 0 (and redosed after 48 hours in 72-hour assays). After a total of 24 and 72 hours, cultures were harvested, counted, and 1 Â 10 6 cells were stained with propidium iodide buffer [10 Ag/mL propidium iodide, 1% (w/v) trisodium citrate, 0.1% (v/v) Triton X-100, 100 Amol/L sodium chloride (Sigma)]. Cell cycle distribution was determined using a Becton Dickinson Flow Cytometer and CellFIT Cell Cycle Analysis software. Each condition was examined in triplicate experiments.
Quantitative reverse transcription-PCR. Cells were seeded at low and high densities (2 Â 10 4 /cm 2 and 8 Â 10 4 /cm 2 , respectively). The subconfluent cultures were harvested after 24 hours whereas the highdensity cultures were cultured until reaching confluence (f48 hours). For treatment, the cells were seeded as subconfluent conditions and treated with fresh medium or vitamin D 3 compounds alone or in combination with TSA as indicated. Total RNA was extracted using the GenElute RNA extraction system (Sigma) according to the instructions of the manufacturer. The cDNA was prepared from RNA (1 Ag) that was initially heated to 70jC for 5 minutes with 100 pmol random hexamers (Promega). The RNA was then added to an 18-AL reaction mix, which contained a final concentration of 10 units of avian myeloblastosis virus, 1Â reaction buffer, 1 unit of RNase inhibitor, and 1 mmol/L deoxynucleotide triphosphates. Each reaction was heated for 30 minutes at 37jC, followed by 5 minutes at 95jC.
Expression of specific mRNAs was quantitated using the ABI PRISM 7700 Sequence Detection System. Each sample was amplified in triplicate wells in 25 3 .125 pmol FAM-labeled TaqMan probe, and 22.5 pmol primers. All reactions were multiplexed with preoptimized control primers to ensure parallel amplification with VIC-labeled probe for 18S rRNA (Perkin-Elmer Biosystems, Warrington, United Kingdom). Primer and probe sequences were previously described (20) and were designed for the current study [VDUP-1 forward primer, GCCTGC-TGATTGTCATGGAA; VDUP-1 reverse primer, TGGTCTCCTCGA-TCCTGGAT; VDUP-1 probe, TTTGACGGTGGAGAACTCTTTAGCCGT] or were provided from Assay-on-Demand (cytokeratin 19, Perkin-Elmer Biosystems). Reactions were cycled as follows: 50jC for 2 minutes, 95jC for 10 minutes; then 44 cycles of 95jC for 15 seconds and 60jC for 1 minute. Data were expressed as Ct values (the cycle number at which logarithmic PCR plots cross a calculated threshold line) and used to determine dCt values (dCt = Ct of the target gene À Ct of the 18S). The data were transformed through the equation 2
Àdd Ct to give fold changes in gene expression.
To exclude potential bias due to averaging of data, all statistics were done with dCt values. Measurements were carried out at least thrice in triplicate wells for each condition.
Western immunoblot analysis. Cells were seeded at low and high densities (2 Â 10 , respectively) and either harvested after 24 hours (subconfluent) or cultured until the highdensity cultures reached confluency (72 hours) to give subconfluent and confluent cultures, respectively. Whole-cell lysates were prepared at indicated time points and Western immunoblot analysis was done as previously described (17) . Briefly, 30 Ag of total protein for each sample were electrophoresed on an SDS-polyacrylamide gel, transferred onto polyvinylidene difluoride membrane (Immobilon-P, Millipore, Bedford, MA), and blocked with TBS-Tween 20 containing 5% milk powder for 1 hour. For detection of cyclin E, a rabbit polyclonal antibody (C4976, Sigma) was diluted 1:500. The secondary antibody was horseradish peroxidase conjugated (Amersham, Buckinghamshire, United Kingdom) and diluted 1:2,000. Proteins were detected using enhanced chemiluminescence (Amersham) and autoradiography. To ensure even loading and transfer of protein, membranes were stripped, washed for 15 minutes with TBS-Tween 20, and incubated at 1:5,000 dilution with primary mouse monoclonal h-actin antibody (AC-15, Sigma). An antimouse-horseradish peroxidase secondary antibody was used at 1:3,000 and signals were developed with enhanced chemiluminescence and autoradiography as described above. To quantify the relative changes in protein levels, densitometric analysis was done on the autoradiographs and values were normalized to h-actin levels.
Statistical analysis. The interactions of two compounds were assessed by measuring the mean effect of either compound acting alone (F SE; refs. 20, 21, 33) . The combination of the mean effect for each compound acting alone was the predicted combined inhibition. The mean observed combined inhibition was then compared with this value using the Student's t test. Classification of the inhibitory effects were as follows: strong additive effects were those with an experimental value significantly greater than the predicted value; additive effects were those in which the experimental value did not significantly differ from the predicted value; and subadditive effects were those in which the experimental value was significantly less than the predicted value.
Results
Breast cancer cells show suppressed antiproliferative and gene-regulatory responses towards 1a,25(OH) 2 D 3 . To confirm the extent of the suppressed responsiveness towards 1a,25(OH) 2 D 3 , we compared the effect of 1a,25(OH) 2 D 3 on the proliferation of a panel of breast cancer cell lines with that on nonmalignant MCF-12A cells using clonal proliferation in soft agar and liquid proliferation assays. MCF-12A cells were significantly and acutely inhibited with ED 50 of f20 and f300 nmol/L in the soft-agar and liquid media, respectively (Table 1) . Complete inhibition of clonal proliferation in soft agar was achieved at 100 nmol/L (ED 90 = 70 nmol/L), but not in liquid proliferation assays. In contrast, the malignant cell lines displayed a spectrum of reduced sensitivities towards 1a,25(OH) 2 D 3 (Table 1 ). T47-D was the most sensitive cell line, with an ED 50 in colony formation assay comparable to that of MCF-12A, although it did not display an ED 90 value. The remaining lines all showed greater ED 50 values in soft agar than MCF-12A cells (Table 1) . Indeed, MDA-MB-231 cells did not achieve an ED 50 even at 1,000 nmol/L. The responses of the cancer cell lines towards 1a,25(OH) 2 D 3 in the liquid proliferation assay were all suppressed, compared with MCF-12A cells, with ED 50 values not being achieved.
In contrast to the differential sensitivity displayed by MCF-12A and the breast cancer cell lines towards 1a,25(OH) 2 D 3 , all cell lines displayed comparable and significant responses towards the histone deacetylation inhibitor TSA. The responses to the methytransferase inhibitor 5-aza-dCyd were more heterogeneous (Table 1) .
In an attempt to characterize more fully the apparent insensitivity towards 1a,25(OH) 2 D 3 , we investigated the basal 2 D 3 . Expression essentially plateaued after 3 hours at 10,000-to 100,000-fold increases, compared with control, and was sustained for the duration of the analysis (16 hours). The dynamics in MDA-MB-231 cells was similar but the amplitude was considerably lower (23-fold induction after 6-hour treatment with 1a,25(OH) 2 D 3 P < 0.0001) and thereafter reached a plateau of f100-fold (Fig. 1A) .
A similar, but not so striking, suppressed VDR responsiveness was seen with the other two gene targets, which are more directly associated with antiproliferative VDR effects (20, (34) (35) (36) (37) (38) . GADD45a mRNA expression patterns in MCF-12A cells showed significant peaks at 4 hours (1.4-fold; P < 0.05), which was sustained up to 8 hours; after which, a subsequent 2.1-fold increase occurred at 12 hours (P < 0.05) and decreased thereafter. In MDA-MB-231 cells, the pattern was similar but the magnitude was suppressed at all time points, notably at the 12-hour time point (Fig. 1B) . VDUP-1 mRNA displayed a clear early peak increase after 1 hour (1.7-fold; P < 0.05) in MCF-12A cells but was absent in MDA-MB-231 cells, although a more modest significant peak was detected at 6 hours (Fig. 1C) . In both cell lines, there were cyclical, modest, but not significant, modulation of the VDR at 1, 4, and 7 hours (data not shown). Together, these data suggest that both the antiproliferative and gene regulatory effects of 1a,25(OH) 2 D 3 were repressed in breast cancer cell lines compared with nontumorigenic MCF-12A cells.
Expression and regulation of VDR and corepressors correlate with reduced 1a,25(OH) 2 D 3 sensitivity. We hypothesized that in the cancer cell line panel, the suppressed cellular responses towards 1a,25(OH) 2 D 3 (Table 1 ) and VDR target gene expression (Fig. 1) were determined by an altered relative ratio of the VDR and either one or all of the VDR interactive corepressors. We therefore compared the basal expression of VDR, NCoR1, NCoR2/SMRT, and TRIP15/Alien in malignant T47-D, ZR-75-1, MCF-7, and MDA-MB-231 to that in MCF-12A cells ( Fig. 2A) . T47-D cells displayed similar expression levels of VDR and the three corepressors compared with MCF-12A, which reflected a comparable sensitivity towards 1a,25(OH) 2 D 3 . In contrast, the three remaining cell lines all displayed significant reductions in VDR, coupled with variable changes in corepressor expression. MCF-7 and MDA-MB-231 cells had significantly elevated NCoR1 expression (2-and 1.7-fold increase, respectively; P < 0.05). Interestingly, TRIP15/Alien was also significantly elevated in MCF-7 cells (1.8-fold; P < 0.05) but modestly reduced in MDA-MB-231 cells. Consequently, in the 1a,25(OH) 2 D 3 -resistant cancer cell lines, the ratio of NCoR1 to VDR is increased compared with the normalized one in MCF-12A cells, which is arbitrarily set at 1:1. Thus, in exponentially proliferating MDA-MB-231 cells, the ratio of NCoR1 to VDR is 14:1 ( Table 2) . We sought to dissect further the dynamic expression patterns of the corepressors relative to the VDR and, therefore, we investigated the expression profiles in the four cancer cell lines under differing proliferation conditions. Cell cycle analyses confirmed that subconfluent cultures were associated with increased proportions of actively dividing cells as revealed by an increased percentage of cells in either S or G 2 -M phase. For example, subconfluent MCF-7 cultures had 43 F 2.3% of cells in G 1 and, on confluence, this was significantly increased to 62 F 3.4% (P < 0.05). Subconfluent MDA-MB-231 cultures had 38 F 1.7% of cells in G 1 and, on confluence, this was significantly increased to 60 F 4.2% (P < 0.05). Similar patterns were seen in T47-D and ZR-75-1 (data not shown). These effects were confirmed with elevated cyclin E levels in subconfluent versus confluent cultures (Fig. 2B) .
T47-D cells displayed a clear, significant reduction in the levels of NCoR1 and TRIP15/Alien mRNA at confluence (0.6-and 0.5-fold reduction, respectively, relative to same cell exponential controls; P < 0.05; Fig. 2C ). MDA-MB-231 cells, which had significantly higher basal levels of NCoR1 compared with exponentially proliferating T47-D cells, displayed no downregulation of NCoR2/SMRT, NCoR1, or TRIP15/Alien mRNA in confluent compared with subconfluent cultures. However, comparable analyses in MCF-7 cells revealed a significant reduction in NCoR1 (0.7-fold; P < 0.05) on confluence (Fig. 2C) . Viewed in this way, the graded ability to regulate corepressors, and in particular NCoR1, also correlates closely with 1a,25(OH) 2 D 3 sensitivity (Table 2 ; Fig. 2C ). Together these data support a model where NCoR1 is up-regulated in cells and this level is sustained, irrespective of proliferation status, in the most 1a,25(OH) 2 D 3 recalcitrant cells.
Corepressors are elevated in ERa-negative tumors. To investigate further the significance of deregulated corepressor expression in breast cancer, we examined 21 matched tumor and normal breast cancer samples. To allow for epithelial enrichment in the tumor samples, the relative levels of corepressors were normalized to cytokeratin 19 mRNA, an established marker of mammary epithelial cells (39) . There was considerable variation in the level of the VDR in both the ERapositive (14 of 21) and ERa-negative (7 of 21) tumors with a mean fold change of 4.9 F 2.1 and 11.8 F 7.3, respectively, compared with the matched normal, although there was significant variation (Fig. 3A) .
These data were then transformed further by normalizing the corepressor expression data to the level of VDR in tumor sample to reveal the ratios of corepressor to VDR, which are shown in Fig. 3B to D. This ratio was noticeably increased in the ERa-negative tumors whereas it was decreased in the ERapositive tumors. Thus, the mean ratio of the NCoR1 to VDR was 0.25 F 0.1:1 in the ERa-positive tumors and 4.2 F 1.4:1 in the ERa-negative tumors, with similar changes in the ratios of SMRT/NCoR2 and TRIP15/Alien to VDR. Interestingly, the level of either NCoR1 or SMRT/NCoR2 positively correlated with the VDR [R 2 = 0.45 and 0.66; P < 0.0006 and P < 4 Â 10
À6
, respectively], suggesting that the levels of corepressors were coregulated with the VDR.
Targeting elevated corepressor levels in 1a,25(OH) 2 D 3 -insensitive cancer cell lines with histone deacetylation or methylation inhibitors. The above data indicate that corepressors are elevated in breast cancer cell lines and in primary cancer tissue, notably in ERa-negative tissue. Furthermore, at least in cell lines, deregulation of NCoR1 expression correlates with diminished responsiveness to 1a,25(OH) 2 D 3 . These data suggest that elevated levels of corepressors may inappropriately sustain acetylation of histone lysine residues and thereby Fig. 2 . Fold elevation of nuclear corepressor mRNA levels in breast cancer cell lines. A,VDR and corepressor mRNA levels measured by quantitative reverse transcription-PCR inT47-D, ZR-75-1, MCF-7, and MDA-MB-231compared with MCF-12A nonmalignant breast epithelial cells. Total mRNA was isolated from triplicate cultures in mid-exponential phase, reverse transcribed, and the target genes amplified in triplicate as described in Materials and Methods. *, P < 0.05; **, P < 0.01; ***, P < 0.001. B, protein was isolated from parallel subconfluent (S) and confluent (C) MCF-7 and MDA-MB-231cells (Materials and Methods) and resolved by SDS-PAGE and probed with antibody to cyclin E. Representative blots are shown with the position of the proteins indicated on the left. Blots were subsequently stripped and reprobed for h-actin. C, the fold reduction in the mRNA levels of NCoR1, NCoR2/SMRT, andTRIP15/Alien was measured in confluent cultures ofT47-D, ZR-75-1, MCF-7, and MDA-MB-231, compared with subconfluent controls, by quantitative reverse transcription-PCR. Points, mean of three separate experiments amplified in triplicate wells; bars, SE.
reduce the ability of the VDR to initiate transcription. Histone deactylation leading to chromatin condensation has been shown to form a template for DNA methyltransferases to initiate a more stable long-term silencing of gene loci (40 -42) . Therefore, we reasoned that the relative 1a,25(OH) 2 D 3 insensitivity associated with elevated NCoR1 could be countered by cotreatment with minimally active ED 25 These studies revealed that generally the strongest individual agent effects were observed in MCF-12A cells. That is, whereas MCF-12A cells were potently inhibited by each agent individually, they did not display any significant co-operativity. Indeed, with a few cotreatments (e.g., with vitamin D 3 compounds plus 5-aza-dCyd), the observed effects were actually significantly suppressed compared with the predicted effects. By contrast, there was enhancement of observed over predicted effect by cotreatment with TSA in the cancer cell line models. Importantly, the extent of the co-operative interactions correlated with the altered ratio of NCoR1 to VDR and was most pronounced in the ERa-negative cell line MDA-MB-231. Thus, combinations of RO-26-2198 with TSA were additive in T47-D, whereas in ZR-75-1 and MDA-MB-231, these effects were converted to strong additive interactions (Table 2) .
Changes in cell cycle distribution associated with vitamin D 3 compounds plus TSA treatments. The antiproliferative actions of vitamin D 3 in various cell models have been associated with induction of G 1 cell cycle arrest and/or induction of apoptosis (18, 43, 44) , and we examined the extent to which MCF-12A cells displayed either of these responses. After 24-hour exposure to 1a,25(OH) 2 D 3 (100 nmol/L), there was a significant accumulation of cells in G 1 (62 F 4%; P < 0.05) compared with 43% in G 0 -G 1 in matched mid-exponentially proliferating control cells and a concomitant reduction in the proportion of cells in S and G 2 -M phase. In parallel, we measured changes in mitochondrial membrane integrity using JC-1 dye, which dimerizes and fluoresces red in healthy mitochondria compared with monomeric green when membrane potential is lost. This approach measures the early commitment of cells toward apoptosis and therefore was examined at 24 and 48 hours using previously optimized protocols (21) . These analyses found only minor, nonsignificant changes, which suggested that the cells were not undergoing apoptosis (data not shown).
Subsequently, we measured the extent to which cotreatments of vitamin D 3 whereas the control cells displayed an accumulation of 38% (F1.5%). Together these data suggest that the cotreatment with agents facilitates co-operative changes in the distribution of the cell cycle, which, in part, contribute to the potency antiproliferative actions.
Regulation of VDR target genes in MDA-MB-231 cells cotreated with RO-26-2198 plus TSA. In line with the hypothesis of epigenetically repressed antiproliferative target genes, we investigated the effects on the regulation of the antiproliferative target genes GADD45a, VDUP-1, and the 1a,25(OH) 2 D 3 -regulatory CYP24. Time-course studies (0-16 hours) in MDA-MB-231 cells were undertaken to investigate the effects of RO-26-2198 alone and in combination with TSA. Treatments with RO-26-2198 alone revealed that patterns and fold changes of GADD45a, VDUP-1, and CYP24 did not significantly differ between 1a,25(OH) 2 D 3 and RO-26-2198 (Figs. 1 and 4) .
By contrast, cotreatment with RO-26-2198 and TSA cooperatively regulated target genes. The induction of GADD45a in MDA-MB-231 cells by either 1a,25(OH) 2 D 3 or RO-26-2198 was characterized by a broad, but suppressed, accumulation of mRNA after 12 hours, and therefore comparable to the pattern observed in MCF-12A cells (Fig. 1B) . Only cotreatment with RO-26-2198 and TSA enhanced the magnitude of the 12-hour peak, resulting in a 2.4-fold increase, which was significantly greater than treatment with either RO-26-2198 or TSA alone (P < 0.05; Fig. 4A) . Interestingly, this level was comparable to the induction in MCF-12A cells treated with 1a,25(OH) 2 D 3 alone (Fig. 1B) . VDUP-1 induction also showed significant enhancement of mRNA accumulation when cotreated with RO-26-2198 plus TSA, notably at 12 hours (2.1-fold versus 1.1-and 1.6-fold for cotreatment versus TSA and RO-26-2198, respectively; P < 0.05; Fig. 4B) .
In contrast to these effects, RO-26-2198 cotreatment with TSA had a complex range of effects on the induction of CYP24. TSA alone had little effect, but at early time points (<5 hours), it squelched RO-26-2198-mediated induction very significantly. For example, at 3 hours, the induction by RO-26-2198 alone was 14.8-fold and TSA significantly reduced this to 6.4-fold (P < 0.0001; Fig. 4C ). At later time points, the patterns were reversed and cells cotreated with TSA plus RO-26-2198 displayed significantly enhanced CYP24 mRNA levels (P < 0.0001) compared with either agent alone (data not shown).
Discussion
The current study has shown that the spectrum of reduced 1a,25(OH) 2 D 3 -responsiveness between nonmalignant breast epithelial cells and cancer cell lines was not determined solely by a linear relationship between the levels of 1a,25(OH) 2 D 3 and VDR. Rather, elevated levels of corepressors, such as NCoR1, in breast cancer cell lines and primary tumors were common and associated with insensitivity towards 1a,25(OH) 2 D 3 . In turn, the NCoR1 complex was targeted by cotreatments of vitamin D 3 compounds plus histone deacetylation inhibitors, which was associated with increased gene regulatory actions and antiproliferative responses. VDR target gene regulation studies revealed that each gene target seemed to have a distinct profile of mRNA accumulation, which often differed between the malignant and nonmalignant background. The complex choreography of nuclear receptormediated transactivation has only recently emerged and involves cyclical rounds of receptor-coactivator complex assembly, recruitment of members of the large ''bridging'' DRIP/ TRAP/ARC complex, which links the receptor complex to the cointegrators CREB-binding protein/p300, and basal transcriptional machinery (9, 10) . In ligand-replete systems, these cycles can be transient (<30 minutes) and include the sequential assembly of receptor complexes followed by subsequent complex disassembly, proteosome-mediated receptor degradation, and/or recruitment of corepressors to remaining receptors to reconstitute repressive complexes (45, 46) . More recently, it has emerged that different response elements respond to ligand in a relatively asynchronous manner with separate, temporal patterns of receptor associations with coactivators and corepressors (e.g., vitamin D response element on the promoter/ enhancer region of the CYP24 gene; ref. 47) .
The pulsatile mRNA accumulation patterns of the target genes VDUP-1 and GADD45a may reflect such spatiotemporal cycling recruitment of apo and holo receptor megacomplexes at individual vitamin D response element on the promoter/ enhance of target genes. We propose that deregulated corepressor levels shift the dynamic equilibrium between apo and holo receptor conformations to histone deacetylation around the vitamin D response element and favor transcriptional repression. Thus, VDR gene targets (e.g., CYP24, GADD45a, and VDUP-1) are less responsive to 1a,25(OH) 2 D 3 in MDA-MB-231 cells compared with MCF-12A cells. Somewhat paradoxically, the basal levels of CYP24 and VDUP-1 are elevated in MDA-MB-231 compared with MCF-12A cells, which suggests that the responsiveness, rather than the absolute expression levels, is targeted for disruption; certainly, there is a clear advantage to be gained in cancer cells by having elevated basal levels of CYP24, which is also a target for amplification in breast cancer (48) .
Increased ratios of corepressor to VDR correlated with loss of sensitivity towards 1a,25(OH) 2 D 3 and elevated proliferative status, suggesting that VDR responsiveness is repressed in post-G 1 cells. Corepressor down-regulation in G 1 may afford a ''window'' of sensitivity towards antimitotic hormones such as 1a,25(OH) 2 D 3 . Possibly reflective of their deregulated proliferative status, frequent corepressor up-regulation was found in ERa-negative primary tumors. Interestingly, in the primary were plated into six-well plates and allowed to grow for 36 hours to ensure that cells were in mid-exponential phase. Cells were treated either with RO-26-2198 (100 nmol/L),TSA (15 nmol/L), the combination of RO-26-2198 plusTSA, or left untreated (control). Total RNA was isolated after the indicated time periods, reverse transcribed, and the target genes amplified and the fold increase calculated as described in Materials and Methods. Points, mean of three separate experiments amplified in triplicate wells; bars, SE. Gene regulation in cells treated with RO-26-2198 plusTSA. A, GADD45a; B,VDUP-1; C, CYP24. *, P < 0.05, treatments that were significantly greater than control (for GADD45a and VDUP-1). *, P < 0.0001, treatments that were significantly greater than control (for CYP24). tumor material, NCoR1 and SMRT/NCoR2 levels were positively correlated with VDR levels. These data suggest that where the VDR is elevated, it may actually provide a benefit to the tumor. First, the increased ratio of NCoR1 to VDR may drive apo receptor complexes to assemble on the promoter/enhancer region of target genes and, therefore, form a template for subsequent more stable epigenetic silencing of these regions. Second, it may allow cytoplasmic VDR actions to suppress apoptosis via nontranscriptional interactions (49) . Elevation of NCoR1 and NCoR2/SMRT found in the current study may in part explain the relative insensitivity of other breast cancer cell lines (BT-474, BT-20, HBL-100, and SK-BR-6) found by others (18, 50) . Equally, we surveyed five known ERa-negative cell lines and found >2-fold increase in NCoR1 expression levels in four (MDA-MB-175, BT-20, HBL100, and HMT3532) compared with T47-D cells (data not shown).
Metabolism of 1a,25(OH) 2 D 3 limits VDR-mediated signaling. Consequently, we focused on a metabolically stable analogue of 1a,25(OH) 2 D 3 . However, the potency of this analogue was significantly enhanced further by the cotreatment with TSA, suggesting that ligand availability is not the sole ratelimiting factor in gene regulation. These studies revealed that increased ratio of corepressor to VDR predicted enhanced responsiveness to combinations of vitamin D 3 compounds plus TSA. These antiproliferative responses were associated with increased G 1 accumulation and reflected the acute antiproliferative response displayed by MCF-12A cells towards 1a,25(OH) 2 D 3 . These data are supported by our earlier preliminary study, which showed significant strong additive effects in clonogenic assays with MDA-MB-231 cells treated with 1a,25(OH) 2 D 3 at doses as low as 1 nmol/L combined with TSA (51) .
Cotreatment with vitamin D 3 compounds plus TSA may act to shift the equilibrium point between the apo and holo receptor complexes to favor a more transcriptionally permissive environment and facilitate transactivation, reflecting the greater metabolic stability of RO-26-2198; cotreatment with TSA significantly increased the levels of GADD45a and VDUP-1, notably at later time points. Parallel studies in prostate cancer also identified that GADD45a induction was repressed in androgen receptor -independent cancer models. Equally, the levels of GADD45a reexpression were comparable to those found in MDA-MB-231 cells and were shown to equate to a significant increase in protein levels (20) . By contrast, induction of CYP24 was initially suppressed by the cotreatment with vitamin D 3 compounds plus TSA. Other mechanisms are likely to play a part. For example, TSA may act to increase the expression of a negative regulator such as YY1, which has been shown to suppress transcription by the VDR on the CYP24 promoter (52) . Presumably, the limited effect of this effect is related to the metabolism of TSA (53) .
Collectively, our data support the hypothesis that the actions of the VDR are suppressed by an epigenetic mechanism, which attenuates the ability to regulate target genes. In support of this, we found that cancer cells with reduced antiproliferative sensitivity towards 1a,25(OH) 2 D 3 also showed suppressed regulation of three VDR target genes, which in turn correlated with the ratios of corepressor to VDR. In addition, a similar spectrum of ratios was found in ERa-negative primary tumors. Sensitivity of breast cancer cell lines towards 1a,25(OH) 2 D 3 could be enhanced by cotreating with histone deacetylation inhibitors, again most notably in the ERa-negative breast cancer models, underscoring the role of corepressors. This in turn was associated with reexpression of antiproliferative target genes, such as GADD45a, to a level that was comparable to that observed in nonmalignant models. GADD45a is an ideal candidate for a repressed VDR target gene (i.e., basal expression is comparable in all cell models) but regulation is suppressed in 1a,25(OH) 2 D 3 -insensitive cells.
From these data, we suggest a model whereby in ERa-positive disease, NCoR1 and NCoR2/SMRT levels are reduced, reflected by the reduced ratio of expression to VDR, thereby enhancing estrogenic signaling. By contrast, ERa-negative tumors, which have arisen either de novo or as a result of tamoxifen treatment, are not reliant on estrogenic hormones, and instead elevation of NCoR1 silences VDR and other antimitotic nuclear receptors. These findings reflect our previous studies in prostate cancer (20, 21) . Equally these patterns will be compounded by the roles that these corepressors play in regulating other transcription factor actions (54 -56) . The current study adds to a growing body of data, which underscores the importance of the coactivator/corepressor milieu to determine nuclear receptor actions in physiology and pathophysiology (57 -61) .
Finally, these studies suggest that the VDR is not overtly disrupted by genetic or cytogenetic mechanisms in cancer, but rather epigenetic mechanisms selectively attenuate the transcriptional responsiveness. Such mechanisms most likely disrupt other receptors, resulting in reduced sensitivity to a wide range of dietary-derived macronutrient and micronutrient ligands. Thus, measurement of ratios of corepressor to receptors, such as VDR in tumor samples, may have significant prognostic and therapeutic value. The current study has highlighted the potential to establish novel chemotherapies centered around histone deacetylation inhibitors, such as TSA, or the clinically relevant suberoylanilide hydroxamic acid, in combination with potent dietary-derived nuclear receptor ligands, to deliver a more focused and sustained ''anticancer'' regimen for estrogen-independent disease.
